May 31,2022

OncoHealth and Blue Note Therapeutics Partner to Provide a Digital Therapeutic for Treating Cancer-related Anxiety and Depression Symptoms

Blue Note Therapeutics, a prescription digital therapeutics (PDT) company dedicated to easing the burden of cancer and improving outcomes, and OncoHealth, a leading digital health company dedicated to oncology, have partnered to support patients coping with cancer by delivering oncology-specific mental health care. Through OncoHealth’s telehealth platform, Iris™, licensed healthcare professionals can provide Blue Note’s attune™ to patients living with cancer. Attune is the first digital therapeutic program designed to treat anxiety and depression symptoms related to cancer and received Breakthrough Device designation from the U.S. Food and Drug Administration in June 2020.

COLLABORATION PARTNERSHIP

#institution

#telehealth

#dtx

View Analyst & Ambassador Comments
Go to original news
May 10,2022

Kaiku Health enters a strategic partnership to further improve patient outcomes through digital patient monitoring

Kaiku Health, a leading digital therapeutics platform in cancer care, and Roche, a leading global healthcare company, are entering a strategic partnership in digital patient monitoring and management (DPMM). Kaiku Health and Roche aim to deploy digital tools to provide real-time symptom management by patients and Health Care Providers (HCPs), improve patient support, and provide personalised cancer care to cancer clinics and patients globally.

COLLABORATION PARTNERSHIP

#product & service

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 23,2022

Swiss multicentre study to investigate the effect of ePRO-based model of care on early detection and management of immune-related adverse events

Kaiku Health is taking part in a study assessing the use of an electronic Patient-Reported Outcome (ePRO)-based model of care to evaluate onset of symptomatic immune-related adverse events in cancer patients and their detection by healthcare providers. This phase-II randomised controlled trial, comparing the ePRO-based model of care to the current standard model of care, is conducted at the Geneva University Hospitals and Lausanne University Hospital, Switzerland.

CLINICAL STUDY

#platform

#rpm

View Analyst & Ambassador Comments
Go to original news
May 03,2022

Large study shows effectiveness of combining body sensors and GAIA's digital therapeutics system

In this trial, GAIA combined its digital therapeutic software platform with smart sensors, including a sensorized shirt that collects biomedical data (e.g., respiration dynamics, electrocardiogram, body movement) and a predictive algorithm that forecasts the development of individual patients’ depressive symptoms. The goal of the system was to provide personalized feedback and easily accessible treatment options for patients with severe somatic conditions (e.g., cancer, myocardial infarction, and kidney failure), in which depression is often unrecognized and inadequately treated.

CLINICAL STUDY

#dtx

#connected device

View Analyst & Ambassador Comments
Go to original news
May 09,2022

OncoHealth Secures Strategic Investments from Arsenal Capital Partners & McKesson Corporation

OncoHealth, the leading digital health company dedicated to oncology, announced today it has received strategic investments from Arsenal Capital Partners (“Arsenal”), a private equity firm specializing in building transformational healthcare businesses, and from McKesson Corporation (“McKesson”). The investments will support OncoHealth’s innovation and delivery of its oncology-specific digital health solutions for people with cancer, and Arsenal will take a majority ownership stake in the business. Additional financial terms of the transaction were not disclosed.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
May 26,2022

The Impact of COVID-19 on Cancer Diagnosis

Belong.Life, a leading global tech provider of high-engagement patient communities and care platforms, today announced that the American Society of Clinical Oncology (ASCO) has published a Belong.Life abstract in its 2022 Annual Meeting Abstract Book providing new insight into cancer diagnosis and reactivation following COVID-19 infection. The study was based on anonymized data aggregated from the Belong - Beating Cancer Together app, which is used by almost 1 in 10 U.S.-based cancer patients.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 04,2022

Remedy Health Media Partners with Belong.life

Remedy Health Media, a leading digital health platform that serves patients, caregivers, and healthcare providers through a family of trusted digital brands, announced a multi-year commercial partnership with Belong.Life, the creator of one of the largest communities of cancer and multiple sclerosis (MS) patients and caregivers, as well as Belong’s BOS (Belong Operating Systems), a “build-your-own patient community” platform. With a specific focus on cancer and MS, Remedy and Belong will partner to further support these communities with education campaigns, late breaking news, patient-friendly medical conference coverage and in-depth features to further serve patients and care partners looking for additional tools to manage their conditions more effectively.

COLLABORATION PARTNERSHIP

#product & service

#platform

View Analyst & Ambassador Comments
Go to original news
May 06,2022

Using AI to Predict Bone Fractures in Cancer Patients

As medicine continues to embrace machine learning, a new study suggests how scientists may use artificial intelligence to predict how cancer may affect the probability of fractures along the spinal column. In the U.S., more than 1.6 million cases of cancer are diagnosed every year, and about 10% of those patients experience spinal metastasis - when disease spreads from other places in the body to the spine. One of the biggest clinical concerns patients face is the risk of spinal fractures due to these tumors, which can lead to severe pain and spinal instability.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
May 03,2022

Telehealth cancer care consultations during the COVID-19 pandemic: a qualitative study of the experiences of Australians affected by cancer

In response to the onset of the COVID-19 pandemic, telehealth was rapidly rolled out in health services across Australia including those delivering cancer care. This study aimed to understand people with cancer and carers’ experiences with telehealth for cancer care during the COVID-19 pandemic and associated restrictions.

CLINICAL STUDY

#telehealth

View Analyst & Ambassador Comments
Go to original news
May 17,2022

Kent NHS Trusts to Modernise Patient Diagnostics Across the Region with Sectra

The Kent and Medway Medical Imaging Consortium has procured a medical imaging system from Sectra to support faster diagnosis and earlier treatment for patients, and to increase capacity to meet growing demand.

PRODUCT

#ai/software

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY